Luhan Pharmachem Co., Ltd.

Luhan pharmachem Co., Ltd. supplies Rizatriptan Benzoate bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Rizatriptan Benzoate is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Rizatriptan?

Rizatriptan (trade name Maxalt) is a 5-HT1 receptor agonist of the triptan class of drugs developed by Merck & Co. for the treatment of migraine headaches.

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, store 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in Australia, Finland, hospital the United States, Canada and New Zealand.

Indications

Rizatriptan is FDA-approved to treat acute migraine attacks with or without aura. It does not prevent future migraine attacks. Rizatriptan is also used off-label to treat cluster headaches.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, sovaldi textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.